166 related articles for article (PubMed ID: 37663580)
21. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.
Salavert M; Cobo J; Pascual Á; Aragón B; Maratia S; Jiang Y; Aceituno S; Grau S
Adv Ther; 2018 Nov; 35(11):1920-1934. PubMed ID: 30328061
[TBL] [Abstract][Full Text] [Related]
22. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection.
Whitney L; Nesnas J; Planche T
Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671306
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent
Abdali ZI; Roberts TE; Barton P; Hawkey PM
EClinicalMedicine; 2020 Jul; 24():100420. PubMed ID: 32637898
[TBL] [Abstract][Full Text] [Related]
24. Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.
Al Momani LA; Abughanimeh O; Boonpheng B; Gabriel JG; Young M
Cureus; 2018 Jun; 10(6):e2778. PubMed ID: 30112254
[TBL] [Abstract][Full Text] [Related]
25. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States.
Jiang Y; Sarpong EM; Sears P; Obi EN
Infect Dis Ther; 2022 Feb; 11(1):111-126. PubMed ID: 34292496
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate
Ford DC; Schroeder MC; Ince D; Ernst EJ
Am J Health Syst Pharm; 2018 Aug; 75(15):1110-1121. PubMed ID: 29903711
[TBL] [Abstract][Full Text] [Related]
27. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Crawford T; Huesgen E; Danziger L
Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
[TBL] [Abstract][Full Text] [Related]
28. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
29. Treatment of pediatric
D'Ostroph AR; So TY
Infect Drug Resist; 2017; 10():365-375. PubMed ID: 29089778
[TBL] [Abstract][Full Text] [Related]
30. Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.
Chaparro-Rojas F; Mullane KM
Infect Drug Resist; 2013; 6():41-53. PubMed ID: 23843696
[TBL] [Abstract][Full Text] [Related]
31. Fidaxomicin for the treatment of Clostridium difficile infections.
Whitman CB; Czosnowski QA
Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
[TBL] [Abstract][Full Text] [Related]
32. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
[TBL] [Abstract][Full Text] [Related]
33. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
34. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
van Prehn J; Reigadas E; Vogelzang EH; Bouza E; Hristea A; Guery B; Krutova M; Norén T; Allerberger F; Coia JE; Goorhuis A; van Rossen TM; Ooijevaar RE; Burns K; Scharvik Olesen BR; Tschudin-Sutter S; Wilcox MH; Vehreschild MJGT; Fitzpatrick F; Kuijper EJ;
Clin Microbiol Infect; 2021 Dec; 27 Suppl 2():S1-S21. PubMed ID: 34678515
[TBL] [Abstract][Full Text] [Related]
35. European Practice for CDI Treatment.
Fitzpatrick F; Brennan R; van Prehn J; Skally M; Brady M; Burns K; Rooney C; Wilcox MH
Adv Exp Med Biol; 2024; 1435():57-84. PubMed ID: 38175471
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH
J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and management of Clostridium difficile infection.
Dupont HL
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
[TBL] [Abstract][Full Text] [Related]
39. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
Miller M
Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
[TBL] [Abstract][Full Text] [Related]
40. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection.
Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL
Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]